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ABSTRACT
Cerebral palsy is a disease that puts a great mental burden on caregivers and generates very high social costs. Children with 
CP require many years of rehabilitation and medical care. The etiology of the disease is undoubtedly multifactorial, and the 
pathogenesis is associated with focal damage to the central nervous system. One can find descriptions of well-documented 
interventions in the literature that reduce the risk of CP in certain groups of pregnant and neonatal patients, and interven-
tions that have a potentially protective effect. In this review, we have analyzed the available literature in terms of prenatal 
and postnatal interventions that may have an impact on reducing the incidence of this condition in children.
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CEREBRAL PALSY — DEFINITION
Cerebral Palsy (CP) is a heterogeneous group of diseases 
whose common denominator is non-progressive damage 
to nerve tissue at an early stage of development. Symptoms 
of CP include irregularities in movement and posture. The 
range of possible damage is unusually large, and the very 
diagnosis of CP does not determine the degree of disability 
of a patient or the type of damage to the central nervous 
system. Children affected by CP include both independent 
patients and patients incapable of leading an independent 
existence. Co-existing problems may include intellectual, 
cognitive and sensory disorders as well as epilepsy and be-
havioral disorders. According to the definition, the damage 
is not progressive, but the general condition can change 
over the years due to treatment and the plasticity of the 
maturing nervous system.
EPIDEMIOLOGY AND ETIOLOGY
CP occurs in the population with a frequency of 1.3– 
–2.5/1000 live births [1]. The biggest risk factors for CP are 
premature delivery and low birth weight. Among new-
borns with a mass between 1000 and 1499 g, the inci-
dence is 60.04/1000 live births, and among newborns with 
a mass between 1500 and 2499 g, the rate is 8.33/1000 live 
births. Among newborns born before 28 weeks of preg-
nancy, the incidence of CP is estimated at 111/1000 live 
births, which decreases to about 1.35 among newborns 
born after 36 weeks of pregnancy (below the level for the 
general population). Despite these strong correlations be-
tween low gestational age and low birth weight, over half 
of children with cerebral palsy are born after week 36 of 
pregnancy [2]. In the case of premature babies, the risk of 
developing CP increases with complications resulting from 
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premature birth such as periventricular leukomalacia, intra-
ventricular bleeding and bronchopulmonary dysplasia [3]. 
The etiology of CP is undoubtedly multifactorial. In addition 
to premature delivery, the risk factors include intrauterine 
growth restriction (IUGR), intrauterine infections, antepar-
tum hemorrhage, multiple pregnancy, placental pathology 
as well as congenital defects (mainly of the central nervous 
system) and genetic predisposition [3–5]. Although most 
of the causative factors occur in the prenatal and perinatal 
periods, about 10–18% of CP is the result of CNS damage 
during infancy and early childhood [5], i.e. during intensive 
brain development. They include sepsis, meningitis, ker-
nicterus, head trauma, severe hypoxia and stroke (which is 
a consequence of, among other things, a congenital heart 
disease, vascular malformations or thrombotic disorders).
Despite significant progress in perinatal care, fetal moni-
toring during pregnancy and intranatally and an increase in 
the number of caesarean sections, no reduction in popula-
tion incidence of CP was achieved [1]. There is a perception 
among the public (also in the medical community) that most 
CP cases are caused by hypoxic-ischemic injury during de-
livery. The American College of Obstetricians and Gynecolo-
gists and the American Academy of Pediatrics published 
objective criteria for intranatal asphyxia in 2003 (Tab. 1) [6].
Among Australian cohorts of neonates born in term, only 
4% of patients met the criteria for intranatal asphyxia [7].
SYMPTOMATOLOGY
The extent of an expanding brain can be different, 
which translates into a large spectrum of different applica-
tions. Symptoms can only apply to precise movements or 
an independent existence. Despite the fact that access to 
the clinical presentation is limited and changes over time, 
it inhibits and changes the child’s motor development. Di-
agnosis of CP is established over a period of time, never 
on a one-time basis. The first symptoms may be discreet, 
including emerging problems with gaining new skills by the 
child and problems with counteracting gravitational forces, 
e.g. lack of ability to stabilize the head and torso, sitting or 
walking in the expected period of life. Such symptoms, de-
pending on the accuracy of the interview, suggest the first 
suspicion of the diseases. An experienced clinician is able 
to detect alarming symptoms, such as muscle exercises, 
fixed asymmetry, abnormal spontaneous motility, early. 
Therefore, children at risk (e.g. premature babies) must be 
referred to specialist care before other measures are taken. 
It is important to note that the problem may reveal itself 
after several different activities related to an apparently 
healthy full-term newborn, despite the absence of disturb-
ing signs in the first days of life. The transformation of the 
brain is irreversible, however, due to the plasticity of the 
CNS, the damaged function may be taken over by other 
areas of the brain.
PREVENTION — PROCEDURES TO REDUCE 
THE RISK OF CP
Factors that damage the central nervous system can act 
at different stages of the development of the human brain, 
which is why potential preventive measures relate to dif-
ferent time frames.
Considering prematurity and low birth weight as the 
largest CP risk factors in the pediatric population, all in-
terventions used in the prevention of preterm labor have 
potential protective effects. Randomized studies indicate 
the effectiveness of progesterone in the prevention of pre-
term births in specific patient groups. Patients with a history 
of preterm labor [8, 9] and patients with a short cervix in 
a single pregnancy benefit from prophylactic progesterone 
supplementation [9, 10], studies also indicate the effective-
ness of progesterone in twin pregnancy with a short cervix 
in the second trimester, however, the strength of scientific 
evidence is lesser in this case [11, 12]. Shepherd et al. [13] 
found only one randomized work estimating the direct 
effect of the use of progesterone in CP reduction in their 
systematic review, 17-hydroxyprogesterone caproate was 
used intramuscularly in patients with single pregnancy and 
a history of premature labor, despite a reduction in the 
incidence of premature labor observed before 37 weeks of 
pregnancy [relative risk (RR) = 0.66, 95% confidence interval 
(CI) = 0.54–0.81], a reduction in neonatal intraventricular 
hemorrhage (RR = 0.25, 95% CI = 0.08–0.82), the efficacy of 
progesterone during pregnancy in reducing CP incidence 
compared to mothers receiving placebo has not been con-
firmed (RR 0.14, 95% CI 0.01–3.48) [13]. It should be noted 
that the majority of conducted randomized trials to assess 
the effects of progesterone in the prevention of preterm 
labor were not designed to assess distant effects in children, 
so the research group in the said study is relatively small 
(a total of 274 children in the research group and placebo), 
which may result in insufficient statistical power to detect 
differences in the occurrence of complications with relatively 
low prevalence in the general population.
Table 1. Criteria for intranatal asphyxia (AAP, ACOG) [6]
Neonatal signs consistent with an acute peripartum or 
intrapartum event:
1. Apgar score of < 5 at 5 minutes and 10 minutes
2. Fetal umbilical artery acidemia: fetal umbilical artery pH < 7.0,  
or base deficit ≥ 12 mmol/L, or both
3. Neuroimaging evidence of acute brain injury seen on brain MRI 
or MRS consistent with hypoxia-ischemia
4. Presence of multisystem organ failure consistent with hypoxic-
ischemic encephalopathy
MRI — magnetic resonance imaging; MRS — magnetic resonance 
spectroscopy; AAP — American Academy of Pediatrics; ACOG 
— American College of Obstetricians and Gynecologists
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Another intervention having proven effect in the preven-
tion of premature labor is the use of cervical cerclage along 
with cervical shortening in the second trimester of pregnan-
cy, which reduces the risk of labor before 37 and 34 weeks of 
pregnancy by an average of 23% (RR = 0.77 95% CI 0.66–0.89) 
[14]. The meta-analysis did not show greater efficacy of the 
cervical cerclage, compared to placebo in reducing intraven-
tricular hemorrhage, periventricular leukomalacia, respiratory 
distress syndrome (RDS) and necrotizing enterocolitis (NEC). 
We have not found studies assessing the long-term effects 
of this intervention on children in the literature, including 
assessing the development of cerebral palsy.
We cannot overlook the importance of using low doses 
of acetylsalicylic acid in the prevention of preeclampsia (PE) 
and intrauterine fetal growth disorder (IUGR) [15]. Preec-
lampsia is a dangerous complication for both the mother 
and the child. It is the cause of iatrogenic prematurity be-
cause the only effective treatment is childbirth. An ASPRE 
randomized study assessing the effectiveness of acetylsali-
cylic acid compared to placebo showed a 62% reduction in 
PE prevalence before 37 weeks of gestation [16]. The study 
also assessed the risk of fetal growth disorders, which are 
one of the main risk factors for CP as well, the risk of having 
a baby with a weight < 10 percentile was 23% lower, and 
with a weight < 3 percentile was 8% lower [16]. There are no 
studies in the literature directly assessing the effect of using 
low doses of acetylsalicylic acid in the prevention of PE on 
the incidence of CP, however, it seems that PE screening and 
the use of ASA in high-risk patients may have a beneficial 
effect in the prevention of CP in the population. This issue, 
however, requires further prospective research.
Antenatal steroid therapy
Antenatal steroid therapy has been used for almost 
50 years in obstetrics. A published meta-analysis of 30 ran-
domized studies confirmed the efficacy of antenatal steroid 
therapy in preventing RDS in newborns (RR = 0.66, 95% 
CI 0.56–0.77), preventing perinatal death of newborns 
(RR = 0.72 CI 95% 0.58–0.89), intraventricular bleeding 
(RR = 0.54 CI 95% 0.43–0.69), NEC (RR = 0.50, 95% CI 0.32–
–0.78) and the development of sepsis in the first two days 
of life (RR 0.60, 95% CI 0.41–0.88) [17]. Studies of the Polish 
population have also shown a reduction in the risk of RDS, 
bronchopulmonary dysplasia and mortality of neonates 
born ≤ 32 weeks of pregnancy [18]. The abovementioned 
beneficial effects for newborns beg the question about the 
long-term effect on the occurrence of CP in the population 
of premature babies. In the cited meta-analysis, Roberts et al. 
[17] take into account five randomized studies assessing the 
occurrence of this complication. There was no significant dif-
ference between groups in the occurrence of CP (RR = 0.60 CI 
95% 0.34–1.03, p = 0.06), however, it should be noted that 
the achieved relative risk value is close to statistical signifi-
cance. Given the proven effects of antenatal steroid therapy, 
it is currently not possible to perform placebo-controlled or 
randomized controlled trials for ethical reasons. Another 
meta-analysis, that also included observational studies, in-
dicates the clinical benefits of a single course of antenatal 
steroid therapy in reducing the risk of CP diagnosed in the 
first year of life or later, the percentage of CP diagnoses was 
32% lower in patients whose mothers received a course of 
steroid therapy during pregnancy terminated prematurely 
(RR = 0.68, 95% CI 0.56–0.82). Steroid therapy also reduced 
the risk of severe disability (RR = 0.79, 95% CI 0.73–0.85) [19].
THE USE OF MAGNESIUM SULFATE (MGSO4)
A meta-analysis including five randomized studies 
evaluating the effectiveness of magnesium sulfate in the 
prevention of CP in the population of premature babies is 
available in the literature. The upper gestational age limit at 
the stage of randomization was between 30 and 34 weeks of 
pregnancy [20]. The meta-analysis showed a 30% reduction 
in the incidence of CP in the case of children born before 
32–34 weeks of gestation (RR = 0.70, CI 95% = 0.55–0.89) and 
moderate or severe CP by 40% (RR = 0.60, CI 95% = 0.43– 
–0.84). The composite endpoint of cerebral palsy or death did 
not reduce significantly in the entire study population (RR = 
0.92, 95% CI 0.83–1.03), however, a reduction was observed 
in the subgroup of randomized patients in studies assessing 
only neuroprotective effects (RR 0.85, 95% CI 0.74–0.98). 
The meta-analysis did not report that in utero exposure to 
magnesium sulfate increased the risk of neonatal death. The 
number of patients to treat in order to prevent one case of 
cerebral palsy was 46 in the pregnancy group < 30 weeks 
of pregnancy, and 56 in the pregnancy group of gestational 
ages between 32 and 34 weeks since the last menstrual 
period (95% CI 26–187). Magnesium sulfate administration 
protocols differed between the studies, however, an in-
tervention always began with a dose of 4–6 g in the first 
20–30 min, then the infusion was continued at 2 g/h for 12 h 
or 1 g/h for 24 h. The neuroprotective mechanism of magne-
sium sulfate is unknown. At least four potential therapeutic 
models are postulated: prevention of glutamate excitotox-
icity on the postsynaptic membrane by blocking NDMA 
receptors, antioxidant and anti-inflammatory properties as 
well as fetal cerebral circulation properties [21]. Only one 
of the randomized studies included the long-term effects 
of magnesium sulfate treatment. In a multicenter ACTO-
MgSO4 study in which patients giving birth < 30 weeks ges-
tation were randomized (n = 1062), the born children were 
included in an early-school-age medical examination [22]. 
The mean corrected age at the time of the study time was 
8.4 years old in both the study group and the placebo group. 
The occurrence of cerebral palsy did not differ significantly 
725
Jakub Mlodawski et al., Cerebral palsy and obstetric-neonatological interventions
www. journals.viamedica.pl/ginekologia_polska
between the groups [odds ratio (OR) = 1.26, 95% CI 0.84–
1.91, p = 0.27], nor did the mortality of patients in both 
groups (RR = 0.80 95% CI 0.62–1.03, p = 0.08). The observed 
relative risk of mortality had a p-level close to 0.05, which 
implies the need for further studies due to the possibility 
of type II error associated with insufficient statistical power 
(the power of comparison in the study was 80%).
Currently, the World Health Organization recommends 
the administration of magnesium sulfate to patients who are 
at a high risk of preterm labor in both single and multiple 
pregnancies within the next 24 hours, and whose gesta-
tional age is less than 34 weeks of pregnancy [23]. It is recom-
mended to administer 4–6 g in a bolus within 20–30 minutes 
followed by an infusion for 24 h — 1–2 g/h. The infusion 
should be continued until delivery, and if no delivery occurs 
one day after the treatment had started, the infusion should 
be terminated. The American College of Obstetricians and 
Gynecologists in its opinion from 2010 (which was upheld 
in 2018) and the Royal Society of Gynecologists and Ob-
stetricians, in a scientific opinion from 2011, recommend 
the administration of magnesium sulfate in threatening 
preterm labor. Despite evidence of its effectiveness in the 
literature, there is a need for further studies to assess optimal 
dosage, gestational age and obstetric results in the absence 
of preterm labor as well as long-term effects.
DELAYED CORD CLAMPING
Early cord clamping is defined as tightening of the um-
bilical cord within 60 seconds after birth, while late umbilical 
cord clamping takes place after 1 minute of life (optimally 
2–3 minutes) or after the ripening of the umbilical cord. After 
birth, thanks to the continuous exchange of blood in the 
pulsating umbilical cord between the placenta of the mother 
and the newborn, the so-called placental transfusion, mostly 
in the first 3 minutes after birth. The time gained until the 
umbilical cord is tightened allows the newborn to change 
physiologically and transit from fetal to ectopic life. Late cord 
clamping, recommended by numerous scientific societies 
and WHO [24], has a beneficial effect on the child’s health 
and nutrition. It is also safe for mother. There is no increase 
risk for maternal adverse outcome like postpartum hemor-
rhage, lower postpartum hemoglobin levels or the need for 
blood transfusion. It is recommended for both full-term and 
premature babies. In the absence of spontaneous breathing 
in the first seconds after birth, stimulation (drainage, tactile 
stimulation) should be performed before the umbilical cord is 
tightened and respiratory resuscitation begins. Early umbili-
cal cord clamping is necessary only in strictly justified cases 
of unstable condition of the child or mother: (a newborn 
requiring immediate respiratory resuscitation, unexpected 
interruption of maternal-fetal circulation (detachment of 
the umbilical cord, separation of the placenta), inhibition of 
intrauterine growth with abnormal flow in the umbilical cord 
because of intrauterine hypoxia resulting in polycythemia 
and increased blood viscosity) [24, 25]. It appears that late 
umbilical cord clamping supports and stabilizes the transfor-
mation of fetal circulation into ectopic circulation in prema-
ture babies and thereby reduces the risk of intraventricular 
bleeding and necrotizing enterocolitis — as indicated by 
some studies and emphasized by WHO in its official rec-
ommendations [24, 26]. Immediate dismissal may result in, 
among others, hypotension provoking the occurrence of 
intraventricular bleeding in the immature brain of premature 
neonates. The latest systematic review evaluating the effects 
of late vs early omphalectomy in 2834 premature newborns 
from 2018 indicates a 30% reduction in hospital mortality (RR 
0.68; 95% CI 0.52–0.90; number needed to benefit 33, 95% CI 
20–100); an increase in hematocrit by an average of 2.73% 
(95% CI 1.94–3.52), a decrease in the risk of blood transfusion 
by 10% (95% CI 6–13%), a higher bilirubin concentration by 
an average of 4 micromoles/L without increasing mortality [27]. 
However, there were no differences in both groups in the 
frequency of severe intraventricular bleeding, brain dam-
age, necrotizing enteritis or late-onset sepsis (chronic lung 
disease, mechanical ventilation) and others. These data con-
tradict the results described in the previous meta-analysis 
from 2012, where it was demonstrated that late umbilical 
cord clamping statistically reduced the risk of these com-
plications in premature babies in a significant manner [28]:
 Ū lower risk of first and second degree intraventricular 
bleeding (RR 0.59, 95% CI 0.41–0.85);
 Ū lower risk of necrotizing enterocolitis (RR 0.62; 95% CI 
0.43–0.9);
 Ū lower risk of anemia requiring transfusion (RR 0.61; 
95% CI 0.46–0.81);
 Ū no difference in the prevention of severe intraventricular 
bleeding (III, IV degree) — however, the authors point to 
the methodological limitations of the study.
The presented data are inconclusive, but none of the 
studies showed a negative impact of delayed cord clamping 
on children born prematurely, while showing the benefits 
that newborns enjoy. The impact on the risk of compli-
cations due to premature birth, including intraventricular 
hemorrhage, requires further analysis.
In the case of term newborns, children benefits from 
delayed cord clamping, first of all, there is a reduced risk of 
iron deficiency in the first months of life, which has a signifi-
cant impact on neurological development. Due to the high 
growth rate, children are very sensitive to iron deficiency, 
which may result in psychomotor retardation in the future, 
and as indicated by epidemiological and experimental 
studies, such abnormalities appearing at an early stage of 
development may be irreversible despite the subsequent 
correction of iron deficiency [29].
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Extensive meta-analysis [30] from 2013 including 
3911 mothers and their newborn babies born on time, as-
sessing early vs late umbilical cord clamping showed: lower 
hemoglobin concentration in the first 24–48 h of life in early 
group neonates [mean difference (MD) — 1.49 g/dL, 95% 
CI 1.78–1.21; n = 884], not observed in the following days of 
life; over twice as high risk of iron deficiency in 3–6 months 
(14% vs 8%, RR 2.65, 95% CI 1.04–6.73, n = 1152) and 40% 
lower risk of phototherapy due to jaundice (2.74% vs 4.36%).
One randomized study, which looked at 263 children 
born from low-risk pregnancies, showed a beneficial effect 
of late vs early umbilical cord clamping on neurological 
development at the age of 4, especially in boys [31].
Umbilical cord milking, i.e. pumping blood from the 
umbilical cord towards the child, should not be confused 
with the late cord clamping process. The optimal time for 
milking or its duration is currently unknown. It is also un-
known whether milking can be an alternative to late umbili-
cal cord clamping, especially in premature babies (studies 
in progress). One study has shown that an alternative to 
delayed cord clamping > 30 seconds can be 4 times milking 
the available cord length at a speed of 20 cm/2 seconds [32].
THERAPEUTIC HYPOTHERMIA
Neonates born after the 35th week of gestation who 
experience a perinatal episode of hypoxia that may result 
in perinatal hypoxic-ischemic encephalopathy, which may 
lead to CP, benefit from therapeutic hypothermia. The use 
of therapeutic hypothermia leads to an improvement in the 
survival rate with normal neurological development at the 
age of 18 months (40% vs 24%, RR 1.63, 95% CI 1.36–1.95) 
and a reduction in the risk of death and major neurological 
disorders at the age of 18 months (48% vs 63%, RR 0.76, 
95% CI 0.69–0.84) [33].
Therapeutic hypothermia must be implemented in the 
first 6 hours of life. This is the approximate latency time be-
tween the primary phase (necrosis) and the secondary phase 
(apoptosis) of biochemical neuronal damage, although it 
has been proven that the more severe the hypoxic-ischemic 
injury, the shorter the latency period [34].
Indications for hypothermia [35]:
 Ū pH ≤ 7.0 (special attention should also be paid to pH 
in the range of 7.01–7.15) and/or BE base deficiency of 
at least 16 mmol/l in a cord blood sample or a blood 
sample taken within 1 hour of life;
 Ū 1 of the following:
•	 Apgar score ≤ 5 in 1, 3, 5, 10 minute after birth;
•	 continuous resuscitation within 10 minutes after 
birth;
 Ū neurological symptoms indicative of moderate/severe 
encephalopathy on clinical excamination (the Sarnat 
scale is used for qualification).
NEONATAL CARE
Intensive and individualized neonatological care in chil-
dren particularly vulnerable to CNS damage (newborns with 
very low birth weight, newborns suspected of hypoxic-is-
chemic encephalopathy) aims to reduce the likelihood of 
long-term neurological sequelae. Over the past 20 years, we 
have seen unprecedented advances in intensive neonatal 
care. Technological development and increasing experience 
have helped to save smaller children and increased effective 
prevention and treatment of typical complications in the 
case of premature neonates.
SUMMARY
The interventions outlined above have proven or poten-
tially protective effects on the risk of CP in children. Even 
though there are no direct studies to assess the reduction of 
CP incidence in the intervention group, we have no doubt 
that the interventions should be part of good medical prac-
tice in every perinatal and postnatal care ward.
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